A difficult political environment for corporations has resulted in non-elected regulators being granted “more latitude,” creating new challenges and unpredictability for the drug industry, Eli Lilly and Company CEO David Ricks said.
“We’re getting I think some different behavior that is hard to plan around, whether it be from the FTC or...







